In this issue:
Panitumumab for advanced right-colon, left-colon and rectal cancers
Prognostic value of primary tumour location and KRAS
Bevacizumab + mFOLFOX6 for RAS-mutant colorectal liver-limited metastases
Trifluridine/tipiracil + bevacizumab for untreated mCRC
Bevacizumab + chemotherapy in elderly (≥75 years) mCRC patients
Impact of age on sequential vs upfront combination chemotherapy
Oligometastatic CRC and first-line chemotherapy
Adjuvant chemotherapy in high-risk colon cancer
Prognostic and predictive tool for stage III colon cancer
Consensus Immunoscore prediction of survival and response to chemotherapy
Please login below to download this issue (PDF)